Validation of a clinical trial composite endpoint for patients with necrotizing soft tissue infections

被引:16
作者
Bulger, Eileen M. [1 ]
May, Addison [2 ]
Dankner, Wayne [3 ]
Maislin, Gregory [4 ]
Robinson, Bryce [1 ]
Shirvan, Anat [3 ]
机构
[1] Univ Washington, Dept Surg, Seattle, WA 98195 USA
[2] Vanderbilt Univ Sch Med, Dept Surg, Nashville, TN USA
[3] Atox Bio Ltd, Ness Ziona, Israel
[4] Biomed Stat Consulting, Philadelphia, PA USA
关键词
Necrotizing soft tissue infection; Fournier's gangrene; clinical trial; composite endpoint; HYPERBARIC-OXYGEN; INTRAVENOUS IMMUNOGLOBULIN; LETHAL SHOCK; MORTALITY; THERAPY; SEPSIS; SCORE; RISK;
D O I
10.1097/TA.0000000000001564
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
OBJECTIVE: Our objective was to develop and validate a composite endpoint for patients with necrotizing soft tissue infections that incorporates: local tissue injury, systemic organ dysfunction, and mortality. METHODS: The Necrotizing Infection Clinical Composite Endpoint (NICCE) was defined as follows:(i) alive at day 28, (ii) three or less debridements before day 14, (iii) no amputation beyond first debridement, (iv) modified sequential organ failure assessment score score (mSOFA) at day 14 <= 1. To be considered a success, all individual criteria must be met. Several data sets were used to assess validity: (i) a retrospective data set of 198 patients treated during 2013 at 12 US trauma centers; (ii) a subset with high disease acuity, admission mSOFA score of 3 or higher (n = 69); and (iii) 40 patients from a multicenter, phase 2 randomized trial of a CD28 immunomodulator (AB103). Clinical success based on each parameter and the composite score was assessed. RESULTS: Using the retrospective data set for all patients and those with high disease severity (respectively), survival rates were 92% and 84%; day 14 mSOFA 1 or lower score was 69% and 51%; three or less debridements was 84% and 77%; and no subsequent amputations were 96% and 94%. Overall, the percent meeting all success criteria for NICCE was 58% (all patients) and 33% (mSOFA > 3). NICCE success was also associated with reduced utilization of health care resources, intensive care unit-free days were median (interquartile range) of 25.3 (21.9-28) and 19.6 (4.3-25.1) days (one-sided Wilcoxon p < 0.001) and ventilator-free days were 28 (26-28) versus 25 (14-28) (p < 0.001) for NICCE success versus failure, respectively. Using the phase 2 data set, the treated group (0.5 mg/kg, n = 15) demonstrated a NICCE success rate of 73.3% versus 40% for placebo (n = 10). CONCLUSION: These data demonstrate internal consistency of the components and face and criterion validity of the NICCE endpoint. NICCE offers an opportunity to demonstrate a clinically relevant treatment effect for patients enrolled in clinical trials for necrotizing soft tissue infection. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:622 / 627
页数:6
相关论文
共 23 条
[11]   Development and Validation of a Necrotizing Soft-Tissue Infection Mortality Risk Calculator Using NSQIP [J].
Faraklas, Iris ;
Stoddard, Gregory J. ;
Neumayer, Leigh A. ;
Cochran, Amalia .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2013, 217 (01) :153-160
[12]   Serial evaluation of the SOFA score to predict outcome in critically ill patients [J].
Ferreira, FL ;
Bota, DP ;
Bross, A ;
Mélot, C ;
Vincent, JL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (14) :1754-1758
[13]   Hyperbaric Oxygen Does Not Improve Outcome in Patients with Necrotizing Soft Tissue Infection [J].
George, Mark E. ;
Rueth, Natasha M. ;
Skarda, David E. ;
Chipman, Jeffery G. ;
Quickel, Robert R. ;
Beilman, Greg J. .
SURGICAL INFECTIONS, 2009, 10 (01) :21-28
[14]   Outcome of Necrotizing Skin and Soft Tissue Infections [J].
Gunter, Oliver L., Jr. ;
Guillamondegui, Oscar D. ;
May, Addison K. ;
Diaz, Jose J. .
SURGICAL INFECTIONS, 2008, 9 (04) :443-450
[15]  
Hadeed George J, 2016, J Emerg Trauma Shock, V9, P22, DOI 10.4103/0974-2700.173868
[16]   Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis [J].
Jallali, N ;
Withey, S ;
Butler, PE .
AMERICAN JOURNAL OF SURGERY, 2005, 189 (04) :462-466
[17]  
Kaempfer R, 2002, ISR MED ASSOC J, V4, P520
[18]   Local variations in the epidemiology, microbiology, and outcome of necrotizing soft-tissue infections: a multicenter study [J].
Kao, Lillian S. ;
Lew, Debbie F. ;
Arab, Samer N. ;
Todd, S. Rob ;
Awad, Samir S. ;
Carrick, Matthew M. ;
Corneille, Michael G. ;
Lally, Kevin P. .
AMERICAN JOURNAL OF SURGERY, 2011, 202 (02) :139-145
[19]   Intravenous immunoglobulin in necrotizing fasciitis - A case report and review of recent literature [J].
Koch, C. ;
Hecker, A. ;
Grau, V. ;
Padberg, W. ;
Wolff, M. ;
Henrich, M. .
ANNALS OF MEDICINE AND SURGERY, 2015, 4 (03) :260-263
[20]   Hyperbaric oxygen therapy in necrotizing soft tissue infections [J].
Massey, Paul R. ;
Sakran, Joseph V. ;
Mills, Angela M. ;
Sarani, Babak ;
Aufhauser, David D., Jr. ;
Sims, Carrie A. ;
Pascual, Jose L. ;
Kelz, Rachel R. ;
Holena, Daniel N. .
JOURNAL OF SURGICAL RESEARCH, 2012, 177 (01) :146-151